The Spine Biologics Market was valued at USD 3.02 billion in 2023 and is projected to grow significantly, reaching USD 4.73 billion by 2032, with a steady CAGR of 5.13% during the forecast period from 2024 to 2032. The rising prevalence of spinal disorders, advancements in biological therapies, and increased demand for minimally invasive procedures are key factors driving this growth.Key Market ..